Abstract
Treatment failure in cancer remains a main clinical challenge and can be attributed to various obstacles, including tumour resistance to therapy, adoption of generalised protocols devoid of required personalised and specific requirements, etc. Although some of the current treatment alternatives consider the differences, for instance, pertaining to tumour microenvironment specificity, litt…